The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Emerging immunotherapies for AML
Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the emerging immunotherapies for acute myeloid leukemia (AML). Specifically, T-cell enhancing therapies, macrophage-enhancing agents, bispecific antibodies and CAR-T cells are discussed. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
